series a
Stage
1
Investors
About
Gila Therapeutics is a clinical-stage biotech developing a first-of-its-kind Topical Lingual Signaling platform (micro-dose PYY & GLP-1 melts on the tongue) to target brain regions that regulate food intake and metabolism for the treatment of obesity, type 2 diabetes, and cardiometabolic disorders, with no expected systemic exposure and a favorable Phase I safety profile.
Explore Gila Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.